Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating disease through the inhibition of the complement system, which is a component of the immune system, at the level of C3, the central protein in the complement cascade. The company's clinical program targets C3 with Phase 3 clinical trials of its main product candidate, APL-2, in multiple indications. APL-2 has the potential to be a treatment that address the limitations of existing treatment options or provide a treatment option. The company is also conducting a Phase 2 trial of APL-2 in glomerular diseases, including C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy and lupus nephritis.